With upcoming IRA price negotiations, potential PBM rebate structure reforms, and increasing regulatory scrutiny of DTC and compounded GLP-1 providers, employers must stay current with their formulary and coverage decisions
Medicare Coverage of Weight Loss Drugs Could Save the U.S
Underwood CR, Parthier C, Reedtz-Runge S (2010) Structural basis for ligand recognition of incretin receptors
This article is for general educational purposes and is not a substitute for an in-person medical evaluation, diagnosis, or treatment
Glucagon-like-peptide-2 (GLP-2) is a similar compound that is typically not considered an incretin due to its lack of glycemic effects
Therefore, for now, it is better to focus on the conclusions that tirzepatide is safe from a cardiovascular perspective